AI drug hunter Iambic files for Nasdaq IPO - BioXconomy
Why now
Thesis: AI biotech IPO pipeline expands
Catalyst to watch: IPO pricing and terms
Main risk: Early-stage company, unproven pipeline
Why it matters
AI drug-discovery IPO adds a new listing but terms and valuation are undisclosed.
Sources
- googlenews · news.google.com · 2026-09-24 11:33 UTC